Moleculin Requests Authorization from the Polish Government to Advance Annamycin

Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, today announced that has submitted its request for Clinical Trial Authorization (“CTA”) in Poland which, if allowed, will enable a clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”) in Poland.